Dr. Weight moved to the Denver area to establish a practice closer to his family. He believes that his patients are an extension of that family and he takes great care to foster meaningful relationships with anyone under his care. He takes pride in helping patients and their families understand the disease process so that they may make informed decisions that fit their personal goals.


Monday: 8am - 5pm
Tuesday: 8am - 5pm
Wednesday: 8am - 5pm
Thursday: 8am - 5pm
Friday: 8am - 5pm
Saturday: Closed
Sunday: Closed
Monday: All day
Tuesday: All day
Wednesday: All day
Thursday: All day
Friday: All day
Saturday: All day
Sunday: All day

Qualifications and experience

Blood / Lymphatic System, Blood / Lymphatic System - Bleeding Disorders, Blood / Lymphatic System - Blood Disorders, Blood / Lymphatic System - Clotting Disorders, Cancers, Cancers - Cancer Medicine, Cancers - Cancer Prevention, Cancers - Living with Cancer, Cancers - Melanoma, Cancers - Skin Cancer, Hematology, Internal Medicine, Medical Oncology
Languages spoken
Thomas Jefferson University Program

Drexel University College of Medicine/Hahnemann University Hospital Program

Medical School
Kansas City University of Medicine and Biosciences College of Osteopathic Medicine

Drexel University College of Medicine/Hahnemann University Hospital Program

University of Missouri (MO)

University of Missouri - Columbia

Clinical interest for patients

I enjoy taking care of patients with all types of cancer and blood disorders. My background is in the treatment of skin cancers such as melanoma and I provide specialized care for those patients who have been diagnosed with skin cancer, past or present.

Research interest for patients

Dr. Weight has served as Principle Investigator for a number of clinical trials focused on the treatment of melanoma and other skin cancers. He co-authored a multi-center study of Nivolumab for the treatment of resected high-risk melanoma patients. Other research interests include the study of circulating biomarkers such as circulating tumor DNA and circulating tumor cells to advance understanding of how these markers can be used in the management of clinical disease.